company background image
2511 logo

HighTide Therapeutics SEHK:2511 Stock Report

Last Price

HK$1.19

Market Cap

HK$658.9m

7D

26.6%

1Y

-90.4%

Updated

24 Dec, 2024

Data

Company Financials

HighTide Therapeutics, Inc.

SEHK:2511 Stock Report

Market Cap: HK$658.9m

2511 Stock Overview

An investment holding company, engages in the discovery, research and development, and commercialization of therapies for the treatment of metabolic and digestive diseases in Mainland China. More details

2511 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

HighTide Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for HighTide Therapeutics
Historical stock prices
Current Share PriceHK$1.19
52 Week HighHK$13.18
52 Week LowHK$0.72
Beta0
1 Month Change13.33%
3 Month Change30.77%
1 Year Change-90.39%
3 Year Changen/a
5 Year Changen/a
Change since IPO-90.39%

Recent News & Updates

We're A Little Worried About HighTide Therapeutics' (HKG:2511) Cash Burn Rate

Oct 05
We're A Little Worried About HighTide Therapeutics' (HKG:2511) Cash Burn Rate

Is HighTide Therapeutics (HKG:2511) In A Good Position To Invest In Growth?

Jun 21
Is HighTide Therapeutics (HKG:2511) In A Good Position To Invest In Growth?

Recent updates

We're A Little Worried About HighTide Therapeutics' (HKG:2511) Cash Burn Rate

Oct 05
We're A Little Worried About HighTide Therapeutics' (HKG:2511) Cash Burn Rate

Is HighTide Therapeutics (HKG:2511) In A Good Position To Invest In Growth?

Jun 21
Is HighTide Therapeutics (HKG:2511) In A Good Position To Invest In Growth?

Shareholder Returns

2511HK BiotechsHK Market
7D26.6%-2.3%2.3%
1Y-90.4%-6.0%22.4%

Return vs Industry: 2511 underperformed the Hong Kong Biotechs industry which returned -6.5% over the past year.

Return vs Market: 2511 underperformed the Hong Kong Market which returned 21.1% over the past year.

Price Volatility

Is 2511's price volatile compared to industry and market?
2511 volatility
2511 Average Weekly Movement15.8%
Biotechs Industry Average Movement11.5%
Market Average Movement8.8%
10% most volatile stocks in HK Market18.5%
10% least volatile stocks in HK Market4.0%

Stable Share Price: 2511's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2511's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
201168Liping Liuwww.hightidetx.com

HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of therapies for the treatment of metabolic and digestive diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis; in phase III clinical trial to treat type 2 diabetes mellitus; is in phase II clinical trial to treat severe hypertriglyceridemia; and in phase II clinical trial to treat primary sclerosing cholangitis, as well as in phase II clinical trial to treat primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug, which is in phase I clinical trial for the treatment of alcoholic hepatitis; HTD1804 that is in preclinical trial to treat obesity; HTD1805, a multifunctional small molecule drug, which is in preclinical trial for the treatment of metabolic diseases; and HTD2802 that is in preclinical trial for treating inflammatory bowel disease.

HighTide Therapeutics, Inc. Fundamentals Summary

How do HighTide Therapeutics's earnings and revenue compare to its market cap?
2511 fundamental statistics
Market capHK$658.91m
Earnings (TTM)-HK$639.20m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2511 income statement (TTM)
RevenueCN¥0
Cost of RevenueCN¥0
Gross ProfitCN¥0
Other ExpensesCN¥600.51m
Earnings-CN¥600.51m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.17
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 2511 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 07:23
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HighTide Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution